should i try tirzepatide Do You Have to Stay on for Life? Treatment Duration Explained Switching between weight-loss medications -

Excess visceral adiposity is strongly associated with: Type 2 diabetes mellitus and insulin resistance Cardiovascular disease and hypertension Non-alcoholic fatty liver disease (NAFLD) Certain cancers, including colorectal and breast cancer Metabolic syndrome According to NHS guidance, waist circumference measurements exceeding 94 cm in men and 80 cm in women (for white European populations) indicate increased metabolic risk, largely driven by visceral fat accumulation

Processed meats like bacon, hot dogs, and deli meat

Similarly, injecting in the abdomen and then wearing a tight waistband creates friction that aggravates the site

Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF

Coadministration with other GLP-1 RAs should be avoided